T
Tetsuya Nakatsura
Researcher at Kumamoto University
Publications - 159
Citations - 5584
Tetsuya Nakatsura is an academic researcher from Kumamoto University. The author has contributed to research in topics: Immunotherapy & Antigen. The author has an hindex of 36, co-authored 146 publications receiving 4597 citations. Previous affiliations of Tetsuya Nakatsura include Kurume University.
Papers
More filters
Journal ArticleDOI
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
Yoshinori Imamura,Toru Mukohara,Yohei Shimono,Yohei Funakoshi,Naoko Chayahara,Masanori Toyoda,Naomi Kiyota,Shintaro Takao,Seishi Kono,Tetsuya Nakatsura,Hironobu Minami +10 more
TL;DR: 3D- Cultured cells forming dense MCSs may be better than 2D-cultured cells in simulating important tumor characteristics in vivo, namely hypoxia, dormancy, anti-apoptotic features and their resulting drug resistance.
Journal ArticleDOI
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Tetsuya Nakatsura,Yoshihiro Yoshitake,Satoru Senju,Mikio Monji,Hiroyuki Komori,Yutaka Motomura,Seiji Hosaka,Toru Beppu,Takatoshi Ishiko,Hidenobu Kamohara,Hiroshi Ashihara,Toyomasa Katagiri,Yoichi Furukawa,Shigetoshi Fujiyama,Michio Ogawa,Yusuke Nakamura,Yasuharu Nishimura +16 more
TL;DR: GPC3, as defined in this study was shown to be a useful tumor marker for cancer-diagnosis for large numbers of patients with HCC.
Journal ArticleDOI
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Yu Sawada,Toshiaki Yoshikawa,Daisuke Nobuoka,Hirofumi Shirakawa,Toshimitsu Kuronuma,Yutaka Motomura,Shoichi Mizuno,Hiroshi Ishii,Kohei Nakachi,Masaru Konishi,Toshio Nakagohri,Shinichiro Takahashi,Naoto Gotohda,Tadatoshi Takayama,Kenji Yamao,Katsuhiko Uesaka,Junji Furuse,Taira Kinoshita,Tetsuya Nakatsura +18 more
TL;DR: This is the first study to show that peptide-specific CTL frequency can be a predictive marker of OS in patients with HCC receiving peptide vaccination.
Journal ArticleDOI
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Hirofumi Shirakawa,Hitomi Suzuki,Manami Shimomura,Motohiro Kojima,Naoto Gotohda,Shinichiro Takahashi,Toshio Nakagohri,Masaru Konishi,Nobuaki Kobayashi,Taira Kinoshita,Tetsuya Nakatsura +10 more
TL;DR: GPC3 expression is correlated with a poor prognosis in HCC patients and is identified as an independent prognostic factor for the overall survival.
Journal ArticleDOI
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Hiroyuki Komori,Tetsuya Nakatsura,Satoru Senju,Yoshihiro Yoshitake,Yutaka Motomura,Yoshiaki Ikuta,Daiki Fukuma,Kazunori Yokomine,Michiko Harao,Toru Beppu,Masanori Matsui,Toshihiko Torigoe,Noriyuki Sato,Hideo Baba,Yasuharu Nishimura +14 more
TL;DR: It is found that the GPC3144-152 (FVGEFFTDV) peptide could induce peptide-reactive CTLs in HLA-A2.1 (HHD) transgenic mice without inducing autoimmunity.